ASCVD risk with persistent hypertriglyceridaemia: What is the latest guidance from ACC?
Dr Michael Miller, Professor of Cardiovascular Medicine at the University of Maryland, Baltimore, USA, explains that the ACC’s expert consensus decision pathway stratifies patients with atherosclerotic cardiovascular disease (ASCVD) and persistent hypertriglyceridaemia according to their residual LDL-cholesterol (LDL-C) level.
